Aethlon Medical, Inc. (AEMD) Balance Sheet

The downward trend in total assets suggests that the company is consuming its resource base without achieving the clinical milestones necessary to replenish capital. This trajectory implies that the business model remains entirely dependent on external financing, as the lack of revenue-generating assets prevents any organic expansion of the balance sheet.

While the current ratio of 3.85 appears superficially healthy, it is heavily skewed by the limited nature of current liabilities rather than robust cash reserves. Investors should interpret this liquidity profile as a temporary buffer that is rapidly depleting, likely necessitating further dilutive equity issuance in the near term.

The consistent growth of this deficit suggests that the company has yet to find a path toward operational self-sufficiency, effectively eroding shareholder value over time. This trend implies that future equity raises may be required not just for growth, but to offset the ongoing destruction of capital inherent in the current clinical-stage model.